National Medical Products Administration
PulseAugur coverage of National Medical Products Administration — every cluster mentioning National Medical Products Administration across labs, papers, and developer communities, ranked by signal.
5 day(s) with sentiment data
-
China gene therapy deaths spark global debate on safety and oversight
Two recent deaths in China linked to gene therapy trials have reignited debates surrounding transparency and regulatory oversight in the field. These incidents, occurring under China's investigator-initiated trial pathw…
-
Shenyang Blower Works Group IPO approved; Moonshot AI raises $3.5B
Shenyang Blower Works Group has received approval from the China Securities Regulatory Commission to list on the Shanghai Stock Exchange's main board. In other news, a subsidiary of Changchun High-Tech, Jinsai Pharma, h…
-
7-Eleven parent abandons Polish investment; AI leader predicts 'old world's' end
Seven & i Holdings, the parent company of 7-Eleven, has decided not to proceed with its investment in Żabka Group, Poland's largest convenience store operator, due to disagreements over investment terms. The potential d…
-
Fosun Pharma subsidiary gets nod for Parkinson's drug trial
Fosun Pharmaceutical has announced that its subsidiary, Fosun Wanbang, has received approval from the National Medical Products Administration to conduct clinical trials for DM1001, a treatment for idiopathic Parkinson'…
-
Lifang Pharmaceutical subsidiary's eye drop application accepted
Lifang Pharmaceutical's subsidiary, Hefei Norite Pharmaceutical, has received a "Notice of Acceptance" from China's National Medical Products Administration for its polyvinyl alcohol eye drops. These eye drops function …
-
China's drug industry accelerates AI-driven deal-making
China's pharmaceutical sector is increasingly leveraging artificial intelligence to discover and develop new drug candidates, aiming to fuel a new wave of domestic and international deals. The nation is already a signif…
-
Jiudian Pharmaceutical receives drug approvals for hypertension and respiratory treatments
Jiudian Pharmaceutical has received drug registration certificates from the National Medical Products Administration for Cilnidipine Tablets and Ambroxol Oral Solution. The Cilnidipine Tablets are used for treating hype…
-
Yiling Pharma subsidiary receives drug registration certificate for Tadalafil tablets
Yiling Pharmaceutical's wholly-owned subsidiary, Yiling Wanzhou International Pharmaceutical Co., Ltd., has received a drug registration certificate from China's National Medical Products Administration for its Tadalafi…
-
Yipin Hong subsidiary's drug candidate APH03867 accepted for clinical trials
Yipin Hong's subsidiary, Guangzhou Yipin Hong Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for its clinical trial application for the innovative drug APH03867. This…
-
Jiangshan Oupai Appoints New Board Secretary; Huiyu Pharma's Cancer Drug Trial Accepted
Jiangshan Oupai has appointed Chen Chunjin as the company's board secretary, effective immediately. This move means the company's chairman, Wu Shuigen, will no longer perform the duties of the board secretary. Separatel…
-
Huayu Pharmaceutical's novel triple-target cancer therapy gains clinical trial approval
Huayu Pharmaceutical's subsidiary, Huayu Haiyue, has received approval from China's National Medical Products Administration to begin clinical trials for HY07121, a novel subcutaneous injection for advanced solid tumors…
-
SpaceX to Join Hang Seng Tech Index Post-IPO; Shanghai Pharma Drug Approved
SpaceX is set to be included in the Hang Seng Hong Kong and US Technology Index following its planned IPO in June 2026. The index provider will recalculate the weighting of its US-listed constituents to equal weight aft…
-
Angelikang Pharma Secures Approval for Etoricoxib Tablet in China
Angelikang Pharmaceutical has received approval from China's National Medical Products Administration for its etoricoxib tablet, a medication used to treat inflammatory conditions like osteoarthritis and gout. This appr…
-
Haisco's novel non-opioid painkiller HSK51155 enters clinical trials
Haisco Pharmaceutical Group has received acceptance for its clinical trial application for HSK51155 tablets from China's National Medical Products Administration. This drug is an orally administered small molecule non-o…
-
China Investment Corp. names new Deputy GM; Apple launches Siri AI
China Investment Corporation announced significant leadership changes, with Liu Haoling stepping down from his roles as Vice Chairman, General Manager, and Chief Investment Officer. Concurrently, Wu Yingchun has been ap…
-
Huadong Medicine subsidiary's facial filler application accepted for new indication
Huadong Medicine's subsidiary, Xinkelimayxue, has received acceptance for a change registration application for its medical device, Ellansé® S-type. This application seeks to expand the approved uses of the injectable p…
-
Dongcheng Pharma seeks approval for injectable nafamostat mesylate
Dongcheng Pharmaceutical's subsidiary, Yantai Dongcheng Northern Pharmaceutical, has received acceptance for its marketing authorization application for injectable nafamostat mesylate. This drug already has similar prod…
-
Kweihua Pharmaceutical's Ambroxol Oral Solution Application Accepted
Kweihua Pharmaceutical's subsidiary has received acceptance for its application to market Ambroxol Hydrochloride Oral Solution. The drug is intended for conditions involving viscous sputum and difficulty expectorating, …
-
US-China biotech rivalry looms amid record deal-making
The United States and China are on the verge of a new technological conflict, with biotechnology emerging as a potential focal point. Despite US pharmaceutical companies seeking drug candidates from China's burgeoning b…
-
Sino Biopharmaceutical partners for exclusive promotion of autoimmune gel
Sino Biopharmaceutical has entered into an exclusive promotion agreement with Beijing Puqi Pharmaceutical Technology for their innovative autoimmune drug, Pumeixiti Ni Gel. This collaboration grants Sino Biopharmaceutic…